Determination of tumour dose response threshold and implication on survival in patients with HCC treated with Y90 radiation segmentectomy: a simple semi-quantitative analysis
- PMID: 33795611
- DOI: 10.1097/MNM.0000000000001420
Determination of tumour dose response threshold and implication on survival in patients with HCC treated with Y90 radiation segmentectomy: a simple semi-quantitative analysis
Abstract
Purpose: To evaluate the relationship between Yttrium-90 (Y90) tumour dose and response rate in patients with hepatocellular carcinoma (HCC) who undergo Y90 radiation segmentectomy (Y90-RS) and to determine implication on overall survival (OS).
Materials and methods: Post Y90-RS Bremsstrahlung single-photon emission computed tomography/CT of 105 HCC patients with 110 treatments performed with glass microspheres was retrospectively analysed. The dose-volume histogram of the targeted tumour was determined with commercially available dosimetry software. Tumour response at 3 months was evaluated using modified Response Evaluation Criteria in Solid Tumours. Tumour dose thresholds associated with the objective response with 80% specificity were then used to evaluate implication on OS using Kaplan-Meier estimation and log-rank analysis.
Results: Tumour dose thresholds to predict objective response with 80% specificity were the following: maximum tumour dose (748 Gy), mean tumour dose (568 Gy), minimum tumour dose of 30% tumour volume (608 Gy), minimum tumour dose of 50% tumour volume (565 Gy), minimum tumour dose of 70% tumour volume (464 Gy) and minimum tumour dose of 100% tumour volume (213 Gy). These parameters all significantly predicted tumour response with areas under the ROC curve of >0.6. Mean tumour dose of ≥250 Gy predicted median OS of 43.67 vs. 17.87 months for others (P = 0.026). Minimum dose ≥180 Gy to 100% of tumour volume predicted median OS of 44.93 vs. 35.87 months for others (P = 0.043).
Conclusion: In patients with HCC undergoing Y90-RS, mean tumour dose ≥250 Gy and minimum tumour dose of ≥180 Gy to 100% of tumour volume are both significantly correlated with higher objective tumour response and prolonged survival.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Similar articles
-
Determination of Tumor Dose Response Thresholds in Patients with Chemorefractory Intrahepatic Cholangiocarcinoma Treated with Resin and Glass-based Y90 Radioembolization.Cardiovasc Intervent Radiol. 2021 Aug;44(8):1194-1203. doi: 10.1007/s00270-021-02834-0. Epub 2021 Apr 22. Cardiovasc Intervent Radiol. 2021. PMID: 33890170
-
Tumor Dose as an Oncologic Predictor of Outcome in Patients with HCC Treated with Resin Y90 Microspheres.Cardiovasc Intervent Radiol. 2025 Aug;48(8):1113-1125. doi: 10.1007/s00270-025-04113-8. Epub 2025 Jul 10. Cardiovasc Intervent Radiol. 2025. PMID: 40640409
-
Achieving Complete Pathologic Necrosis in Hepatocellular Carcinoma Treated with Radiation Segmentectomy before Liver Transplantation: A Comprehensive Glass Microsphere Analysis.Eur J Nucl Med Mol Imaging. 2025 Jul;52(9):3145-3150. doi: 10.1007/s00259-025-07179-1. Epub 2025 Mar 11. Eur J Nucl Med Mol Imaging. 2025. PMID: 40064708
-
Patient Selection and Clinical Outcomes of Y90 in Hepatocellular Carcinoma.Tech Vasc Interv Radiol. 2019 Jun;22(2):70-73. doi: 10.1053/j.tvir.2019.02.006. Epub 2019 Feb 27. Tech Vasc Interv Radiol. 2019. PMID: 31079713 Review.
-
Pictorial essay: imaging findings following Y90 radiation segmentectomy for hepatocellular carcinoma.Abdom Radiol (NY). 2018 Jul;43(7):1723-1738. doi: 10.1007/s00261-017-1391-1. Abdom Radiol (NY). 2018. PMID: 29147766 Review.
Cited by
-
Predictive value of 99mTc-MAA-based dosimetry in personalized 90Y-SIRT planning for liver malignancies.EJNMMI Res. 2023 Jul 3;13(1):63. doi: 10.1186/s13550-023-01011-3. EJNMMI Res. 2023. PMID: 37395912 Free PMC article.
-
Intraarterial Therapies for the Management of Hepatocellular Carcinoma.Cancers (Basel). 2022 Jul 10;14(14):3351. doi: 10.3390/cancers14143351. Cancers (Basel). 2022. PMID: 35884412 Free PMC article. Review.
-
Increased Voxel-Based Y90 Radioembolization Dose to Hepatocellular Carcinoma Improves Imaging Response.Cardiovasc Intervent Radiol. 2025 Jun;48(6):777-785. doi: 10.1007/s00270-025-04001-1. Epub 2025 Mar 10. Cardiovasc Intervent Radiol. 2025. PMID: 40064654
References
-
- International Agency for Research on Cancer. Liver. World Health Organization; 2018.
-
- American Cancer Society. Cancer Facts & Figures 2019. American Cancer Society; 2019.
-
- American Cancer Society. Liver Cancer Survival Rates. American Cancer Society; 2020.
-
- Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, et al. Annual report to the Nation on the Status of Cancer, 1975-2014, featuring survival. J Natl Cancer Inst. 2017; 109:djx030.
-
- Toskich BB, Liu DM. Y90 Radioembolization dosimetry: concepts for the interventional radiologist. Tech Vasc Interv Radiol. 2019; 22:100–111.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical